Simulations Plus
Simulations Plus, Inc. is a software developer specializing in drug discovery and development solutions, focusing on mechanistic modeling and simulation. The company offers a range of software products, including GastroPlus for simulating drug absorption and pharmacokinetics, DDDPlus for laboratory experiment simulations, and ADMET Predictor for predicting molecular properties. Additional tools include KIWI, a cloud-based application for managing drug development data, and various simulation software targeting specific health conditions, such as DILIsym for drug-induced liver injury and RENAsym for kidney injury. Simulations Plus also provides population modeling and simulation services along with clinical pharmacology consulting to support regulatory submissions. The company serves a diverse clientele, including pharmaceutical, biotechnology, and agrochemical industries, as well as academic and regulatory agencies. Founded in 1996 and headquartered in Lancaster, California, it employs over 60 staff members and is known for its contributions to reducing research and development costs in the industry.
Lixoft SAS, founded in 2011 and based in Antony, France, specializes in modeling and simulation software aimed at enhancing drug development processes. The company offers solutions that facilitate population analysis throughout pre-clinical and clinical trials, as well as treatment individualization. By providing user-friendly tools, Lixoft addresses the challenges of integrating data across different phases of drug development, thereby reducing costs and increasing the success rate of new drugs. As of April 2020, Lixoft operates as a subsidiary of Simulations Plus, Inc., further extending its capabilities in the modeling and simulation domain.
DILIsym Services, Inc. specializes in the development of drug-induced liver injury (DILI) simulation software for the pharmaceutical industry, with its flagship product, DILIsym, designed to create predictive models of DILI. This software supports liver safety assessments during clinical drug development, facilitating in vitro to in vivo extrapolation, translating preclinical data into clinical trial designs, and assessing the effects of patient variability on hepatotoxicity predictions. DILIsym includes specialized modules for mitochondrial toxicity, innate immunity, and bile acids. The company also offers NAFLDsym, a tool for evaluating treatments for non-alcoholic fatty liver diseases, as well as consulting services related to its software. Founded in 2015 and based in Research Triangle Park, North Carolina, DILIsym Services originated from the Hamner Institutes, acquiring comprehensive intellectual property and materials for its software. As of 2017, it operates as a subsidiary of Simulations Plus, Inc.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.